- Home
- OPTU vs ARVN Comparison
OPTU vs ARVN Comparison
Compare OPTU & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$1.81
HOLD
Current Price
$12.40
Company Overview
Basic Information| Metric | OPTU | ARVN |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 831.6M | 806.0M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | OPTU | ARVN |
|---|---|---|
| Price | $1.81 | $12.40 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 23 |
| Target Price | N/A | ★ $17.80 |
| AVG Volume (30 Days) | ★ 3.0M | 2.3M |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,642,622,000.00 | $312,300,000.00 |
| Revenue This Year | N/A | $11.06 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 93.86 |
| 52 Week Low | $1.68 | $5.90 |
| 52 Week High | $3.20 | $22.48 |
Technical Indicators
Market Signals| Indicator | OPTU | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 55.73 |
| Support Level | N/A | $12.47 |
| Resistance Level | N/A | $13.56 |
| Average True Range (ATR) | 0.00 | 0.56 |
| MACD | 0.00 | -0.08 |
| Stochastic Oscillator | 0.00 | 40.00 |
Price Performance
Historical Comparison OPTU
ARVN
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.